A federal appeals court has revived securities fraud claims
against cancer drug developer Ariad Pharmaceuticals, finding the
company may have misled investors in 2012 about the risks of its
leading product, leukemia drug ponatinib.
In a decision on Monday, a three-judge panel of the 1st U.S.
Circuit Court of Appeals said Ariad officials may have been
"knowingly or recklessly misleading" shareholders by touting the
purportedly benign profile of the drug ponatinib, even after
clinical trials found serious cardiovascular problems.
To read the full story on Westlaw Practitioner Insights,
click here: bit.ly/2gYeMbs